{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-171784","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.238118+00:00","generated_at":"2026-06-13T19:31:06.045470+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"XOMA acquires LadRx royalty/milestone rights for arimoclomol and aldoxorubicin for $5M upfront","bullets":["Acquired 100% of LadRx's royalty and milestone rights for arimoclomol (NPC) and aldoxorubicin (ImmunityBio).","Paid $5M upfront; additional milestone payments of up to $6M may be required.","Arimoclomol rights: $52.6M net milestones and mid-single-digit royalty from Zevra.","Aldoxorubicin rights: mid-single-digit to mid-teens royalties and up to $343M milestones from ImmunityBio.","Agreements include customary covenants, representations, and indemnification."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-171784","json":"https://secwatch.observer/filing/0001193125-23-171784.json","markdown":"https://secwatch.observer/filing/0001193125-23-171784.md","text":"https://secwatch.observer/filing/0001193125-23-171784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312523171784/0001193125-23-171784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312523171784/d468159d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:31:06.045470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55bd4ac7b5a30d39fa4e40463a62c09d75e71f11","claim":"XOMA Royalty Corp entered into Assignment and Assumption Agreement with LadRx Corporation valued at $5 million upfront, up to $6 million in potential milestone payments (effective 2023-06-21).","evidence_excerpt":"On June 21, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) and a Royalty Purchase Agreement (the “Royalty Purchase Agreement” and together with the Assignment Agreement, the “Agreements”) with LadRx Corporation (“LadRx”), a Delaware corporation.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312523171784/0001193125-23-171784-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"LadRx Corporation"},{"label":"Value","value":"$5 million upfront, up to $6 million in potential milestone payments"},{"label":"Effective","value":"2023-06-21"}],"fact_type":"material_agreement"},{"claim_id":"bd86ca08324a1c1c6c261299d448348dc7138b4c","claim":"XOMA Royalty Corp entered into Royalty Purchase Agreement with LadRx Corporation valued at $5 million upfront, up to $6 million in potential milestone payments (effective 2023-06-21).","evidence_excerpt":"On June 21, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) and a Royalty Purchase Agreement (the “Royalty Purchase Agreement” and together with the Assignment Agreement, the “Agreements”) with LadRx Corporation (“LadRx”), a Delaware corporation.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312523171784/0001193125-23-171784-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"LadRx Corporation"},{"label":"Value","value":"$5 million upfront, up to $6 million in potential milestone payments"},{"label":"Effective","value":"2023-06-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}